Kurt Prins
,
Credentials
MD, PhD

Associate Professor of Medicine, Cardiovascular Division
Biography

Bio

Administrator Info
Name: Lisa Moe
Phone:
Email: seif0046@umn.edu
Fax: 
Mail: Cancer & Cardiovascular Research Building
Lillehei Heart Institute
1st Floor Mailroom CCRB
2231 6th Street SE
Minneapolis, MN 55455

Summary
Dr. Prins is dedicated to understanding right ventricular (RV) dysfunction in pulmonary hypertension. He studies the RV in clinical studies as well as his basic science laboratory. He has given talks at multiple international conferences and receives grant funding from the NIH. Come work with us! Visit https://med.umn.edu/lhi/about/jobs to see open positions in the Prins lab.

Research Summary

  • Pulmonary Hypertension
  • Right Ventricular Failure
  • CTEPH
  • Clinical Trial Participation
  • Pulmonary Balloon Angioplasty

Teaching Summary

  • Cardiac Physiology

Clinical Summary

CTEPH, Invasive hemodynamics, Pulmonary embolus, Pulmonary artery hypertension, Pulmonary hypertension and right heart failure, Right ventricular dysfunction

Education

MD, University of Minnesota

Honors and Recognition

Butrous Young Investigator Award in Pulmonary Arterial Hypertension
2019
American Society of Clinical Investigation Young Physician-Scientist Award
2019
Yang Wang Cardiology Research Fellowship Award
2017
Northwestern Cardiovascular Young Investigator Forum Finalist
2016
Ruth L Kirschstein National Research Service Award (2015-2018)
Mentored Clinical Scientist Research Career Development Award (2018-2023)
Selected Publications

Selected Publications

Prins, K.W., S. Duval, J. Markowitz, M. Pritzker, and T. Thennappan. 2017. Chronic Effects of PAH-Specific Therapy in World Health Organization Group III Pulmonary Hypertension: A Systematic Review and Meta-Analysis. Pulm Circ. 1: 145-155.,
Prins, K.W., L. Rose, S.L. Archer, M. Pritzker, E.K. Weir, F. Kamirczak, J.R. Misialek, T. Thenappan. 2018. Disproportionate right ventricular dysfunction and poor survival in group 3 pulmonary hypertension. Am. J. Respir. Crit. Care Med., 197(11):1496-1499.,
Prins, KW, Thenappan, T, Kalra, R, Weir, EK, Prtizker, M, and Archer, SL. 2019. Repurposing Medications for Pulmonary Arterial Hypertension: What’s Old is New Again. JAHA, 8:e011343,
Rose L*, K.W. Prins*, S.L. Archer, M. Pritzker, E.K. Weir, and T. Thenappan. 2019. Survival in Pulmonary Hypertension due to Chronic Lung Disease: Influence of low diffusion capacity of the lung for carbon monoxide. JHLT. 38: 145-1554. Law, M, Prins, KW, M. Olander, and J.M. Metzger. 2018. Exacerbation of dystrophic cardiomyopathy by phospholamban deficiency-mediated chronically increased cardiac calcium cycling in vivo. AJP Heart. 315: H1544-H1552 ,
Prins, KW, Rose, L, Archer, SL, Weir, EK, Pritzker, M, Olson, M, and Thenappan, T. 2019. Clinical Determinants and Prognostic Implications of Right Ventricular Dysfunction in Pulmonary Hypertension due to Chronic Lung Disease. JAHA, 8: e01146,